AQUINOX PHARMACEUTICALS (AQXP) saw its loss widen to $8.32 million, or $0.36 a share for the quarter ended Mar. 31, 2017. In the previous year period, the company reported a loss of $6.71 million, or $0.39 a share. The company has not recorded any revenues for the current as well as previous quarter.
Operating loss for the quarter was $8.52 million, compared with an operating loss of $6.83 million in the previous year period.
"Highlights of the quarter included continued progress on our LEADERSHIP 301 trial and the addition of two new Directors to our Board," said David Main, president & chief executive officer of Aquinox. "We plan to provide guidance on top line data availability from 301 on our mid-year call in early August as well as provide an update on other pipeline activities."
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: [email protected]
